Coherus Oncology, Inc. (NASDAQ: CHRS)

Coherus Oncology, Inc. is a fully integrated commercial stage oncology company focused on the development and commercialization of immuno oncology therapies. The company's lead product is LOQTORZI, an anti PD 1 antibody approved for the treatment of metastatic or recurrent nasopharyngeal carcinoma. LOQTORZI works by binding to the PD 1 receptor and blocking its interaction with PD L1 and PD L2 ligands, thereby helping the immune system recognize and attack tumor cells. In addition to LOQTORZI, Coherus Oncology advances a pipeline of two clinical stage candidates: casdozokitug targets the immune regulatory cytokine IL 27 to counteract immune suppression in hepatocellular carcinoma, while tagmokitug targets CCR8 on regulatory T cells to reduce immune tolerance in head and neck squamous cell carcinoma and other solid tumors.

Coherus Oncology, Inc. generates revenue primarily from the sale of LOQTORZI in the United States and Puerto Rico through wholesale distributors. Product sales are made to major wholesalers who then distribute LOQTORZI to oncology clinics, hospitals, and specialty pharmacies. The company also receives licensing fees, milestone payments, and royalties from collaboration agreements such as the agreement with Apotex for the commercialization of LOQTORZI in Canada. Additional revenue may arise from future milestones and royalties tied to the development and potential commercialization of its pipeline candidates casdozokitug and tagmokitug.

The company operates through the following segments:

• Reportable Segment: This segment encompasses all research development manufacturing and commercialization activities for Coherus Oncology, Inc.'s immuno oncology portfolio including LOQTORZI, casdozokitug, and tagmokitug.

Coherus Oncology, Inc. holds a distinct position in the immuno oncology market as the only FDA approved therapy specifically indicated for nasopharyngeal carcinoma in the United States. While it competes with established PD 1/PD L1 inhibitors such as Keytruda pembrolizumab from Merck, Opdivo nivolumab from Bristol Myers Squibb, Tecentriq atezolizumab from Genentech, and others, its early line approval in combination with chemotherapy and its preferential placement in NCCN guidelines provide a competitive advantage. The company's pipeline candidates have received special designations; casdozokitug obtained orphan drug status from the FDA for hepatocellular carcinoma and tagmokitug is being evaluated in multiple early stage trials for head and neck squamous cell carcinoma and other solid tumors. These factors, together with its expertise in immuno oncology research and its ability to combine novel mechanisms with existing checkpoint inhibitors, position Coherus Oncology to capture value in niche oncology indications.

Coherus Oncology, Inc. sells LOQTORZI to major wholesale distributors including McKesson Corporation, Cencora Inc, and Cardinal Health Inc. These distributors supply the product to oncology clinics, hospitals, and specialty pharmacies across the United States and Puerto Rico. The company also works with healthcare providers and treatment centers that administer LOQTORZI to patients with nasopharyngeal carcinoma.